Business context and reporting period
The supplied filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018; it is not a Chronoscale Holdings Corp. filing. Ekso develops and sells medical and industrial exoskeletons and provides engineering services. All financial amounts below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial results and condition
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | $2.967 | $1.867 | $5.486 | $3.303 |
| Gross profit | $0.967 | $0.396 | $1.736 | $0.748 |
| Gross margin | 32.6% | 21.2% | 31.6% | 22.6% |
| Operating loss | $(7.185) | $(8.459) | $(15.796) | $(16.600) |
| Net loss | $(7.978) | $(5.507) | $(15.877) | $(13.809) |
| Net loss per share | $(0.13) | $(0.22) | $(0.26) | $(0.58) |
- Revenue growth was primarily driven by higher device sales, especially medical devices. Q2 device and related revenue increased 58%; first-half device and related revenue increased 67%.
- Operating losses narrowed, but net losses increased year over year: Q2 reflected a $3.1 million warrant revaluation gain in 2017 versus a $0.2 million loss in 2018. First-half warrant gains were $0.5 million in 2018 versus $3.0 million in 2017. These noncash fair-value changes make net loss comparisons less reflective of operating performance.
- Cash was $13.890 million at June 30, down from $27.813 million at year-end. Operating cash use was $12.804 million for the first half, versus $16.859 million in 2017; investing cash use was $0.031 million. Financing used $0.994 million, mainly for term-loan principal payments.
- Current assets were $20.403 million and current liabilities $9.395 million; total assets were $23.208 million. Reported note payable was $6.079 million net of discounts and fees ($2.333 million current, $3.746 million noncurrent). The filing’s contractual-obligations table shows $6.875 million of term-loan payments.
- Equity was $7.626 million and accumulated deficit was $160.031 million. Common shares outstanding were 60.832 million at June 30 and 60.832 million as of July 31, 2018.
Material changes versus the prior comparable period
- Higher device sales lifted revenue and gross profit, while gross margin improved in both the quarter and first half.
- Sales and marketing expense rose 20% in Q2 and 23% for the first half, reflecting increased clinical research activity and, in Q2, a $0.175 million charge for an abandoned German sales office. First-half expense also included severance.
- Research and development expense fell 47% in Q2 and 42% for the first half, primarily due to lower employment costs following the May 2017 workforce reduction.
- General and administrative expense rose 14% in Q2 and 31% for the first half. Reported drivers included severance and modified equity awards tied to executive departures, a supplier dispute settlement, and China business-development costs.
- Cash declined by $13.923 million in the first half, compared with a $6.145 million decline in the first half of 2017; the prior period included $10.919 million of net equity and warrant proceeds.
Outlook, risks, contingencies and unusual items
- Going concern and funding: Management stated that forecast cash is insufficient to fund operations for the twelve months after issuance, raising substantial doubt about the company’s ability to continue as a going concern. It estimated resources would cover obligations into the first quarter of 2019 and said significant additional financing is required. Financing may involve equity, debt, collaborations or warrant solicitations; availability and terms are uncertain, and equity financing could dilute shareholders. Without funding, substantial cost reductions or curtailed operations may be necessary.
- Liquidity covenant: The debt agreement required $7.366 million of unrestricted cash at the latest June determination, recalculated monthly. The company reported compliance with this and other covenants at June 30; it estimated effective unrestricted cash at $6.524 million after accounting for the restriction.
- Business plans: Management described continued investment in clinical and sales initiatives for rehabilitation, development and commercialization of a home-use exoskeleton, and industrial products. It is pursuing industrial sales through rental channels and manufacturer relationships. No quantified revenue or earnings guidance was provided.
- Clinical and regulatory: The company reported 84 announced Ekso GT studies, including 53 completed and 31 ongoing, involving nearly 1,900 patients. Adoption, clinical outcomes, regulatory requirements, reimbursement and commercialization remain uncertain.
- Commitments and litigation: Contractual obligations totaled $10.085 million, including $2.200 million of facility operating leases, $0.936 million of purchase obligations, and term-loan and capital-lease payments. The company disclosed three shareholder derivative actions alleging fiduciary-duty and related claims tied to alleged internal-control weaknesses; management considered them without merit and planned to defend them. It also disclosed earlier securities class actions referenced in its prior filings.
- Other risks and changes: Management turnover was identified as a risk to operations, retention and institutional knowledge. Foreign-currency fluctuations affected reported other income/expense; the company said it does not hedge foreign-currency exposure. It adopted revenue-recognition Topic 606 using the modified retrospective method with no opening cumulative adjustment and no material effect on revenue timing or amount.
Important facts for investors to verify
- Whether Ekso secured financing sufficient to address the stated funding shortfall and going-concern uncertainty, and on what terms.
- Subsequent monthly covenant cash requirements, unrestricted cash, operating cash burn and actual runway relative to the first-quarter 2019 estimate.
- Whether device-sales growth and improved gross margins continued, particularly in medical versus industrial products, and whether growth translated into lower operating cash use.
- The progress and outcomes of clinical studies, regulatory status, customer adoption and the commercial performance of rental and industrial-sales channels.
- Developments in the derivative and securities litigation, management transitions, and any resulting costs or changes to controls.
- Potential dilution from financing, equity compensation, and outstanding options and warrants.